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Summary 
Kilovoltage intrafraction monitoring (KIM) is a new real-time 3D image guidance method. Unlike 
previous real-time image guidance methods, KIM uses a standard linac without any additional 
expensive equipment needed. The first clinical trial of KIM is underway for prostate cancer 
radiotherapy. Results from the first 200 treatment fractions show that KIM-guided gating eliminates 
large prostate displacements during treatment delivery. The KIM accuracy and precision are both well 
below one millimeter. 
 
 
*Summary
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Abstract 
Purpose:   
Kilovoltage intrafraction monitoring (KIM) is a new real-time 3D image guidance method. Unlike 
previous real-time image guidance methods, KIM uses a standard linac without any additional 
equipment needed. The first prospective clinical trial of KIM is underway for prostate cancer 
radiotherapy. In this paper we report on the measured motion accuracy and precision using real-time 
KIM-guided gating.   
 
Method and Materials:   
Imaging and motion information from the first 200 fractions from six patient prostate cancer 
radiotherapy VMAT treatments were analyzed.  A 3 mm/5 second action threshold was used to trigger 
a gating event where the beam is paused and the couch position adjusted to realign the prostate to the 
treatment isocenter.  To quantify the in vivo accuracy and precision, KIM was compared with 
simultaneously acquired kV/MV triangulation for 187 fractions.   
 
Results:   
KIM was successfully employed in 197 of 200 fractions.  Gating events occurred in 29 fractions 
(14.5%).  In these 29 fractions, the percentage of beam-on time the prostate displacement was >3 mm 
from the isocenter position was reduced from 73% without KIM to 24% with KIM-guided gating.  
Displacements >5 mm were reduced from 16% without KIM to 0% with KIM.  The KIM accuracy 
was measured to be <0.3 mm in all three dimensions. The KIM precision was <0.6 mm in all three 
dimensions.   
 
Conclusions:   
The clinical implementation of real-time KIM image guidance combined with gating for prostate 
cancer eliminates large prostate displacements during treatment delivery. The in vivo KIM accuracy 
and precision are both well below 1 mm.  
*BLINDED Revised Manuscript (Unmarked)
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Introduction 
There is a history of improvements in radiotherapy technology improving cancer treatment outcomes. 
These advances are particularly evident for prostate cancer where two technologies, intensity 
modulated radiotherapy (IMRT) [1] and pre-treatment image guided radiotherapy (IGRT) [2], have 
demonstrated improved tumor control and lower rates of late rectal toxicity. However, even with 
IMRT and IGRT, intrafraction prostate motion during radiotherapy can simultaneously reduce the 
target dose and expose normal tissues to potentially damaging radiation doses. To address the 
intrafraction motion problem, an evolving class of technologies, real-time image guidance, has 
demonstrated lower toxicity in a matched-pair analysis [3] and dosimetric improvements [4,5] for 
prostate cancer.  
A number of different real-time image guidance methods have been used to treat prostate 
cancer patients including the Real-time Tracking Radiotherapy system [6], CyberKnife linear 
accelerators (frequent x-ray imaging during treatment) [7], Calypso [8], Navotek [9] and RayPilot 
[10]. Emerging real-time guidance technologies include ultrasound [11] and integrated MRI-
radiotherapy systems [12-14]. Common to all of these methods are the need for additional dedicated 
and typically expensive equipment to perform the real-time guidance. Ideally, real-time image 
guidance would be performed on a standard linear accelerator with little modification required. A new 
real-time image guidance technology, kilovoltage intrafraction monitoring (KIM) [15], uses the 
gantry-mounted x-ray imaging system of a standard linac to image and detect the 3D positions of 
implanted markers. The first clinical treatment with real-time KIM occurred in 2014 [16]. Other than 
a description of the first fraction with KIM [16], there have been no reports of the prospective use of 
this real-time image guidance technology.   
In this paper we investigate and quantify the measured motion, accuracy and precision of the 
first 200 treatment fractions of real-time KIM-guided gating for prostate cancer radiotherapy.  
 
3 
Method and Materials 
 
The KIM method 
The KIM theory [17], retrospective clinical results for prostate [18] and liver [19], dose assessments 
[20,21], quality assurance procedure [22] and the description of the first treatment fraction [16] have 
been previously published. The KIM steps are (1) kV imaging during MV treatment, (2) prostate gold 
marker segmentation in the 2D images, (3) 2D→3D reconstruction using maximum likelihood based 
on estimated motion correlations and (4) display of the real-time 3D position.  KIM reads images 
from the gantry-mounted x-ray imager and processes them in real time via steps 1-4 above.   
The KIM deployment was implemented according to the protocol described in [18], with all 
patients imaged at 10 Hz and the KIM implementation performed in real-time, with gating corrections 
as opposed to the retrospective implementation in [18]. Briefly, the protocol for this trial used 10 Hz 
kV imaging at 125 kVp, 80 mA, 13 ms with a 6×6 cm
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 field size. A 120-degree pre-treatment imaging 
kV imaging arc was used to build the probability density function. After gating events, and prior to 
treatment initiation, a 5 second kV imaging sequence was delivered to check if the prostate was still in 
the gated position. The kV beam was on throughout the MV treatment delivery to provide the real-
time guidance. The estimated dose is 0.7 Gy for a 40 fraction treatment, based on the Crocker study 
[21], adjusting for increased imaging frequency (10 Hz not 1 Hz) and decreased average treatment 
time (100s not 200s of beam on). Monthly quality assurance (QA) for KIM followed Ng et al. [22]. 
Patient-specific QA used standard patient-specific VMAT procedures, and in-house developed 
clinical processes to ensure the correct data for the correct patient was used for each treatment.  
Examples of the clinical user interface when motion is within tolerance, and when motion has 
exceeded tolerance and a couch shift is required are shown in Figure 1.  Note that for the current 
version of the software, couch shifts need to be manually performed as an automatic gating interface 
has yet to be developed and would need additional regulatory approval for clinical use.  
 
Patient cohort 
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Six patients provided written informed consent in this ethics-approved trial (NCTxxxx).  The patients 
had biopsy confirmed prostate cancer from AJCC clinical stage T1c to T2.  All patients had 3 gold 
seeds (4.5 mm length, 1.0 mm diameter) implanted into the prostate, were planned with dual-arc 
VMAT and treated on a Trilogy (Varian) linear accelerator.  Patients were treated to 80 Gy in 2 Gy 
fractions. CTV to PTV margins were 7 mm except 5 mm posteriorly. Departmental bowel and bladder 
filling protocols [23] were followed. The time from the pre-treatment imaging arc to the end of the 
last treatment beam was 209 ± 50 (range 145-430) seconds. 
With KIM monitoring, if prostate motion ≥3 mm in any of the three dimensions was observed 
for ≥5 seconds, the treatment was paused and the couch position altered to move the prostate back to 
be aligned with the beam based on the latest measured position.  The 3 mm/5 second threshold was 
based on the results of a dose reconstruction study that showed the CTV D99 is within 4% of the 
planned dose with this action threshold [24]. The first 200 fractions have been analyzed for this study.   
Exclusion criteria for the current version of the KIM software include a lateral pelvic width 
>40 cm, overlapping markers in the axial plane and any hip prosthesis.  
 
Motion measurements 
The KIM software logs the 3D (anterior-posterior, superior-inferior and left-right) positions of each of 
the markers during treatment, enabling the prostate motion to be quantified.  When gating events 
occur, couch shifts are recorded.  The magnitude of the couch shifts enables estimation of the motion 
that would have occurred in the absence of real-time guidance.   
 
Accuracy and precision measurements 
To quantify the accuracy and precision of KIM in vivo, the real-time KIM patient motion 
measurements were compared with simultaneously acquired kV/MV-derived marker triangulation 
results which were considered the ground truth.  Triangulation was performed by determining the 3D 
intersection of the line between the source and marker position on the MV images and the line 
between the source and marker position on the kV images.  The method is shown schematically in 
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Figure 2.  The difference between the individual markers determined with KIM and kV/MV 
triangulation were recorded.  For the measurements the accuracy (mean difference) and precision 
(standard deviation of the differences) were determined.  
 For post-treatment analysis the MV imager was employed to acquire intra-treatment EPID 
images for 187 of the 200 fractions. Based on these images, kV/MV triangulation was performed after 
each fraction to use as a benchmark for the KIM accuracy. Due to the VMAT MLC modulation and 
poorer MV image contrast, the markers were not visible in all MV images. However at least one 
marker was visible in ~11% (i.e. 18,577 of 177,650 total) images, with between 40 and 203 images 
per fraction available for analysis.   
 After the first 80 fractions, small systematic errors were observed. By adjusting the KIM 
calibration, these errors were reduced.  
 
Results 
 
Motion measurements 
KIM was used successfully in 197 fractions of 200 attempted fractions.  The failure in the three 
fractions was due to the operators not adhering to the documented clinical process required to enable 
kV imaging during MV treatment and intra-treatment couch shifts.  When KIM failed, the patients 
were treated with the standard of care (IGRT without real-time guidance). Of the 200 fractions, KIM-
guided gating events per the 3 mm/5 second criteria occurred in 29 fractions (14.5%). The largest 
motion observed was 11.7 mm. 
 An example of KIM measured motion during a fraction with gating events is given in  
 
Figure 3a.  For this patient, two gating events were detected with couch corrections, at 35 seconds and 
before Arc 2. Almost all of the motion is within 3 mm. The prostate motion that would have occurred 
in the absence of real-time guidance is shown in  
 
Figure 3b.  The prostate motion exceeds 5 mm for most of the treatment.   
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The percentage of beam on time that the 3D prostate motion with respect to the isocenter was 
within a given motion value with and without KIM-guided gating for all fractions is shown in Figure 
4.  Also plotted is the subset of measured motion for the 29 fractions with the gating events, and the 
estimated motion for these fractions had no real-time monitoring or gating been used.  
 
Accuracy and precision measurements 
The difference between the KIM and kV/MV triangulation measurements for patient 4 is shown in 
Figure 5.  The measurements show that the accuracy (mean error) and precision (standard deviation of 
error) were below 1 mm. Summary accuracy and precision measurement statistics for all patients and 
fractions are shown in Table 1. We investigated the correlation between the 3D root mean square 
(rms) error and the mean 3D motion within each fraction. We observed a correlation of 0.01 (p = 
0.09) indicating that the observed errors are independent of the KIM-measured motion.  
.  
Discussion 
Given the complexity of prostate motion, Ballhausen et al. [11] conclude “fixed safety margins 
(which would over-compensate at the beginning and under-compensate at the end of a fraction) 
cannot optimally account for intra-fraction motion. Instead, online tracking and position correction 
on-the-fly should be considered as the preferred approach to counter intrafraction motion.” In the 
current paper we report on the clinical implementation of a new online tracking method, kilovoltage 
intrafraction monitoring (KIM), on a standard linac.  Given the wide availability of standard linacs, 
and the routine use of implanted gold markers for prostate cancer IGRT, this makes real-time 
guidance, and the associated clinical benefit [3-5], potentially broadly accessible to cancer patients.   
 KIM–guided gating reduced the prostate displacements.  For the fractions with gating events, 
the percentage of beam-on time the prostate displacement was >3 mm from the isocenter position was 
reduced from 73% without KIM to 24% with KIM-guided gating (Figure 4).  Displacements >5 mm 
were reduced from 16% of the time without KIM to 0% with KIM. Particularly noticeable is the 
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elimination of the large displacements, which have the highest negative dosimetric impact on the 
treatment dose [24].   
The prostate motion measured here is similar to that reported by Su et al. [25] using a 
comparator technology, Calypso.  From 17 patients Su et al. found a 3D prostate displacement of ≥3 
mm for 20% of the time (Figure 1 in their paper) which is similar to the 18% observed for the KIM 
cohort presented here in Figure 4.   
 The clinically determined accuracy of the KIM method, as determined from the kV/MV 
triangulation (Figure 5 and Table 1), demonstrates sub-millimeter accuracy and precision, indicating 
that the error in the KIM system is well below other errors in the radiotherapy process, such as the 
organ motion itself and prostate contouring variability.  The clinically determined accuracy and 
precision measurements are consistent with those determined during commissioning and quality 
assurance procedures [22]. 
 The most widely used clinical real-time prostate monitoring system is Calypso (Varian). KIM 
compares favorably to Calypso in many aspects. KIM uses gold markers that are in standard use for 
IGRT. These are smaller, easier to implant, less costly and more MRI-compatible than those used for 
Calypso. A disadvantage of KIM is the additional x-ray imaging dose required for monitoring. This 
dose is a function of many parameters, including the imaging frequency, the acquisition settings, the 
patient size, and field size [20,21]. Several strategies have been proposed to reduce the imaging dose 
[18] and are the subject of ongoing development.  A potential advantage of using the x-ray images, 
still to be explored, is the reconstruction of the intra-treatment volumetric patient geometry which 
would aid in estimating the anatomy during treatment for prostate and risk organ dose accumulation 
estimates.   
 Further limitations of the current KIM version are the exclusion criteria which include a 
lateral pelvic width >40 cm, overlapping markers in the axial plane and any hip prosthesis. 
Approximately half of the potential patients were excluded.  The pelvic width limitation could be 
overcome by improved image processing and marker segmentation, as well as by allowing an 
increased dose per image, with a lower frame rate so as not to increase the overall patient dose. The 
overlapping marker limitation, which was the highest cause of exclusion, can be overcome by 
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determining the angles where the overlap in the axial plane occurs, and using other angles to build the 
KIM motion model. Accounting for hip prostheses will likely be a compromise in which treatment 
angles where the beam aligns with the hip prostheses will be areas where no motion information is 
possible, with 3D information available during other beam angles. As the AAPM Task Group 63 
report [26] suggests that beam arrangements that avoid the prosthesis should be considered first, this 
limitation may be easily overcome for most patients with prostheses.   
 The KIM system is in-house written software, and not fully integrated with the treatment 
delivery system. Thus there are additional overheads for the treatment process, such as software 
initialization, patient verification and couch correction methods that take additional time compared to 
a treatment without KIM-guided gating. This additional time is sufficiently short (1-3 minutes) that it 
has not impacted the 15 minute time slot scheduled for conventionally fractionated prostate patients.   
 The promising results of the KIM clinical trial to date, summarized in this paper, have 
encouraged a number of future directions. These include the TROG SPARK trial (NCTxxxx) a 
multicenter prospective trial testing the use of KIM in prostate cancer patients being treated with 
Stereotactic Body Radiotherapy (SBRT). The use of KIM for other cancer sites, such as lung and 
liver, is being explored in clinical pilot studies. As rotation as well as translation is emerging as an 
important parameter determining dose delivery accuracy and margins [27], the use of KIM to measure 
rotation to enable real-time 6-degree of freedom image guidance is an active area of research and 
development [28,29].  With the clinical realization of MLC tracking [5] the integration of KIM with 
this technology will enable real-time tracking and adaptation on a standard linear accelerator without 
additional expensive equipment.   
 
Conclusion 
The early results from the first clinical implementation of the novel KIM real-time image guidance 
method have been obtained. When combined with a gating strategy, KIM eliminates large (>5mm) 
prostate displacements during treatment delivery. The in vivo KIM accuracy and precision are both 
well below 1mm.  
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Figure 1.  (a) The KIM user interface when motion is within tolerance. (b) The KIM user interface 
when motion has exceeded tolerance and a couch shift is required. The kV image in the top left of 
each panel shows the real-time acquired kV image overlaid with the marker positions expected from 
planning (green squares) and the real-time detected marker positions (red).  
 
Figure 2.  The accuracy and precision were determined by comparing the motion detected in real time 
by KIM with kV-MV triangulation analyzed post-treatment.  kV = kilovoltage; MV = megavoltage; 
KIM = kilovoltage intrafraction monitoring.   
 
Figure 3.  (a) Prostate displacement measured with KIM-guided gating. (b) Prostate displacement 
estimated without KIM-guided gating.  For KIM-guided gating couch corrections occurred at 60 
seconds (during arc 1) and 170 seconds (before arc 2). The gray shading indicates when the MV beam 
was turned on. A-P = anterior-posterior; S-I = superior-inferior; L-R = left-right.  
 
Figure 4.  Distribution of 3D prostate displacement with respect to the isocenter during beam-on time 
with and without KIM-guided gating. All fractions and those with gating events are shown.  Motion > 
3mm was observed for KIM-guided gating as the gating threshold of >3mm of motion for >5 seconds 
was for motion in any one direction, not the 3D motion. KIM = Kilovoltage intrafraction monitoring; 
Fx = fraction.  
 
Figure 5.  Geometric accuracy results for patient 4 demonstrating sub-mm accuracy (mean error) and 
precision (standard deviation of error). S-I = superior-inferior; A-P = anterior-posterior; L-R = left-
right.   
 
Table 1.  Accuracy and precision measurements over all fractions and patients comparing KIM with 
kV-MV triangulation.   
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Table 1.  Accuracy and precision measurements over all fractions and patients comparing KIM with 
kV-MV triangulation.   
Metric A-P (mm) S-I (mm) L-R (mm) 
Accuracy (mean) 0.10 0.13 -0.26 
Precision (standard deviation) 0.52 0.39 0.52 
5
th
 percentile -0.72 -0.37 -0.69 
95
th
 percentile 0.92 -0.61 0.89 
Abbreviations: A-P anterior-posterior; S-I superior-inferior; L-R left-right.  
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